The Global Preclinical Antibacterial Pipeline - Editors in Conversation
American Society for Microbiology via YouTube
Overview
Syllabus
Introduction
Bacterial Priority Pathogen List
Research and Targeting
CDC vs WHO
WHO fungal pathogen priority list
Methodology
Innovation
Innovation vs Inhibitors
Size of antibacterial research programs
High failure rate of antibacterial compounds
Lack of interest and investment
Pipeline composition
INDEnabling Phase
Mechanism of Action
Narrow Spectrum
Preclinic Programs
Limitations
Future
Taught by
American Society for Microbiology